Ligand Pharmaceuticals Inc. has signed a license agreement with Sermonix Pharmaceuticals LLC for the development and commercialization of oral lasofoxifene in the U.S. and additional territories. Ligand received an undisclosed initial payment and is entitled to receive as much as $45 million in potential regulatory and commercial milestones and royalties of 6% to 10% on future sales. Lasofoxifene is an estrogen partial agonist for the treatment of osteoporosis and other diseases.   “Lasofoxifene...